Change in Royalty payments was expected and more Lovenox generics are likely at some point. Don't be surprised! This stock is not about Lovenox anymore! It's about a strong B/S with boatloads of cash, royalty payments that cover R&D, and THE BEST technology platform for biosimilars. Copaxone approval alone will double the stock! Of course, TEVA will try to stop the product launch, but ultimately that won't work. Then we have the rest of the pipeline and a HUGE addressable market for biosimilars! This could be a $100 stock in 5 years!